Semaglutide for weight management is titrated gradually — commonly 0.25, 0.5, 1.0, 1.7, then 2.4 mg, stepping up about every 4 weeks — to limit gastrointestinal side effects. Higher maintenance doses were tied to greater weight loss in trials.
The standard weight-management titration for semaglutide increases the dose roughly every four weeks — 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg — to reduce nausea and other gastrointestinal effects. In trials, the 2.4 mg maintenance dose drove the largest average weight loss. Your clinician personalizes the pace, and some people stay on a lower dose.
Medical & FDA note: Educational only, not medical advice. Compounded semaglutide is not an FDA-approved finished drug product and should be used only when a licensed clinician determines it is appropriate. Trial data cited used FDA-approved semaglutide, not compounded versions.
Semaglutide for weight management is started low and increased gradually. The schedule below reflects FDA-approved labeling; your clinician may move faster or slower, hold a dose, or keep you at a lower dose that controls appetite and is well tolerated.
| Phase (about 4 weeks each) | Weekly dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | Start low to limit GI side effects |
| Weeks 5–8 | 0.5 mg | Continue titration |
| Weeks 9–12 | 1.0 mg | Continue titration |
| Weeks 13–16 | 1.7 mg | Approach maintenance |
| Week 17+ | 2.4 mg | Maintenance (highest weight-loss dose in trials) |
Illustrative schedule based on FDA-approved semaglutide labeling; your clinician sets the actual pace. Compounded semaglutide is not FDA-approved and dosing should be clinician-directed.
Gastrointestinal effects — nausea, occasional vomiting, constipation or diarrhea — are most common when the dose increases. Gradual escalation gives the gut time to adapt and is the single most effective way to improve tolerability. If a step is poorly tolerated, clinicians often pause or slow the increase rather than push ahead.
Directional illustration of the dose-response seen across semaglutide trials; the 2.4 mg dose produced the largest mean loss in STEP 1 (~14.9%). Individual results vary and lower doses are appropriate for many patients.
Not everyone needs or tolerates 2.4 mg. Some people achieve good appetite control and weight loss at 1.0–1.7 mg with fewer side effects. Staying at a tolerated dose that works is a legitimate strategy — the 'best' dose is the one that balances results and tolerability for you.
Here is the cost trap: many providers price by dose, so your cheap 'starter' month at 0.25 mg is not your real cost. By the time you reach the 2.4 mg maintenance dose — the one tied to the best trial results — your monthly bill may be much higher.
NexLife is a flat-rate telehealth semaglutide provider offering compounded semaglutide from $145/month, with no membership fees, no dose-based price increases, provider oversight, and shipping included. Because the price is flat across eligible doses, the maintenance-dose month costs the same as the starting month.
| Month | Dose | Dose-tiered provider (illustrative) | Flat-rate (NexLife) |
|---|---|---|---|
| Month 1 | 0.25 mg | Lowest tier | $145–$165 |
| Month 3 | 1.0 mg | Higher tier | $145–$165 |
| Month 5+ | 2.4 mg | Highest tier | $145–$165 |
Illustrative structure, not competitor quotes. NexLife advertises a flat rate across eligible doses ($145 on the 12-month plan). Verify all current pricing directly.